Current approaches in chemotherapy of advanced and metastatic non-small cell lung cancer (NSCLC)

Anticancer Research

Volumn 25, Issue 3 A, 2005, Pages 1501-1506

  Reck, Martin ^a  

^a KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Chemotherapy; Non small cell lung cancer (NSCLC); Targeted therapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; ETOPOSIDE; FOLIC ACID ANTAGONIST; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; LONAFARNIB; MITOMYCIN C; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; TENIPOSIDE; TRASTUZUMAB; VINBLASTINE; VINDESINE;

ADVANCED CANCER; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG TARGETING; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HUMAN; LUNG NON SMALL CELL CANCER; META ANALYSIS; METASTASIS; MONOTHERAPY; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SECOND LINE THERAPY; THROMBOCYTOPENIA; TUMOR GROWTH;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS;

EID: 21244485460     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (46)

1. Ginsberg RJ, Goldberg M and Waters PE: Surgery in non-small cell lung cancer. In: Roth JA, Ruckdeschel JC, Weisenburger TH (eds): Thoracic Oncology (ed. 2). Philadelphia, PA, W.B. Saunders Company, pp. 124-146, 1995.
2. Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 311: 899-909, 1995.
3. Stephens RJ, Fairlamb D, Gower N et al: The Big Lung Trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the supportive care setting. Proc Am Soc Clin Oncol 21: 291a #1161, 2002.
4. Schiller JH, Harrington D, Belani CP et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002.
5. Kelly K, Crowley J, Bunn PA Jr et al: Randomized phase III trial of Paclitaxel plus Carboplatin versus Vinorelbine plus Cisplatin in the treatment of patients with advanced non-small cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 19: 3210-3218, 2001.
6. Scagliotti GV, De Marinis F, Rinaldi M et al: Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 20: 4285-4291, 2002.
7. Fosella F, Pereira JR, von Pawel J et al: Randomized, multinational, phase III study of Docetaxel plus platinum combinations versus Vinorelbine plus Cisplatin for advanced non-small cell lung cancer: the TAX 326 study group. J Clin Oncol 21: 3016-3024, 2003.
8. Alberola V, Camps C, Provencio M et al: Cisplatin plus Gemcitabine versus a Cisplatin-triplet versus nonplatinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 21: 3207-3213, 2003.
9. Rudd RM, Gower NH, James LE et al: Phase III randomised trial of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 292a #1164, 2002.
10. Crino L, Scagliotti GV, Ricci F et al: Gemcitabine and Cisplatin versus Mitomycin, Ifosfamide and Cisplatin in advanced non-small cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-3530, 1999.
11. Danson S, Middleton MR, O'Byrne KJ et al: Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer 98: 542-553, 2003.
12. Grigorescu AC, Draghici IN, Nitipir C et al: Gemcitabine (GEM) and Carboplatin (CBDCA) versus Cisplatin (CDDP) and Vinblastine (VLB) in advanced non-small cell lung cancer (NSCLC) stages III and IV: a phase III randomised trial. Lung Cancer 37: 9-14, 2002.
13. Cardenal F, López-Cabrerizo MP, Anton A et al: Randomized phase III study of Gemcitabine-Cisplatin versus Etoposide-Cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 17: 12-18, 1999.
14. Giaccone G, Splinter TA, Debruyne C et al: Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133-2141, 1998.
15. Bonomi P, Kim K, Fairclough D et al: Comparison of survival and quality of life in advanced non-small lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631, 2000.
16. Le Chevalier T, Brisgand D, Soria JC et al: Long term analysis of survival in the European randomized trial comparing Vinorelbine/Cisplatin to Vindesine/Cisplatin and Vinorelbine alone in advanced non-small cell lung cancer. The Oncologist 6(suppl.1): 8-11, 2001.
17. Le Chevalier T, Brisgand D, Douillard JY et al: Randomized study of Vinorelbine and Cisplatin versus Vindesine and Cisplatin versus Vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 14: 687-688, 1996.
18. Negoro S, Masuda N, Takada Y et al: Radomized phase III trial of irinotecan combined with cisplatin for advanced non-small cell lung cancer. Br J Cancer 88: 335-341, 2003.
19. Lilenbaum RC, Langenberg P and Dickersin K: Single agent versus combination chemotherapy in patients with advanced non-small cell carcinoma. Cancer 82: 116-126, 1998.
20. Marino P, Preatoni A, Cantoni A et al: Single-agent chemotherapy versus combination chemotherapy in patients with advanced non-small cell lung cancer: a quality and metaanalysis study. Lung Cancer 13: 1-12, 1995.
21. Lilenbaum RC, Herndon J, List M et al: Single-agent (SA) versus combination chemotherapy (CC) in advanced non-small cell lung cancer (NSCLC): a CALGB randomized trial of efficacy, quality of life (Qo1), and cost-effectiveness. Proc Am Soc Clin Oncol 21: 1a #2, 2002.
22. Sederholm C: Gemcitabine (G) compared with gemcitabine plus carboplatin (GC) in advanced non-small cell lung cancer (NSCLC): a phase III study by the Swedish Lung Cancer Study Group (SLUSG). Proc Am Soc Clin Oncol 21: 291a #1162, 2002.
23. Georgoulias V, Ardavanis A, Agelidou M et al: Preliminary analysis of a multicenter phase III trial comparing Docetaxel (D) versus Docetaxel/Cisplatin (DC) in patients with inoperable advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 1a #2, 2002.
24. Gridelli C, Perrone F and Gallo C: Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 95: 362-372, 2003.
25. Ranson M, Davidson N, Nicolson M et al: Randomized trial of paxlitaxel plus supportive care versus supportive care for patients with advanced non-small cell lung cancer. J Natl Cancer Inst 92: 1074-1080, 2000.
26. Roszkowski K, Pluzanska A, Krzakowski M et al: A multicenter, randomized, phase III study of Docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 27: 145-157, 2000.
27. ELCVSG: Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. Ther Elderly Lung Cancer Vinorelbine Italian Study Group. J Natl Cancer Inst 91: 66-72, 1999.
28. Anderson H, Hopwood P, Stephens RJ et al: Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-small Cell Lung Cancer. Br J Cancer 83: 447-453, 2000.
29. Vokes E, Rosenberg EK, Jahanzev M et al: Multicenter phase II study of weekly oral vinorelbine for stage IV non-small cell lung cancer. J Clin Oncol 13: 637-644, 1995.
30. Jassem J, Ramlau R, Karnicka-Modkowska H et al: Multicenter randomised phase II study of oral versus intravenous vinorelbine in advanced non-small cell lung cancer. Ann Oncol 12: 1375-1381, 2001.
31. Shepherd FA, Dancey J, Ramlau R et al: Prospective randomized trial of Docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum- based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
32. Petrioli R, Pozzessere D, Messinese S et al: Weekly low-dose Docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens. Lung Cancer 39: 85-89, 2003.
33. Lilenbaum RC, Schwartzt MA, Seigel L et al: Phase II trial of weekly Docetaxel in second-line therapy for non-small cell lung carcinoma. Cancer 92: 158-163, 2001.
34. Juan O, Albert A, Ordono F et al: Low-dose weekly paclitaxel as second-line treatment for advanced non-small cell lung cancer: a phase II study. Jpn J Clin Oncol 32: 449-454, 2002.
35. Hanna N, Shepherd FA, Fossella FN et al: Randomized phase III trial of Pemetrexed versus Docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22: 1589-1597, 2004.
36. Fukuoka M, Yano S, Giaccone G et al: Multi-intitutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small cell lung cancer. J Clin Oncol 21: 2237-2246, 2003.
37. Kris MG, Natale RB, Herbst RS et al: Efficacy of Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. A randomized trial. JAMA 290: 2149-2158, 2003.
38. Giaccone G, Johnson DH, Manegold C et al: A phase III clinical trial of ZD 1839 (Iressa) in combination with gemcitabine and cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer (INTACT 1). Ann Oncol 13(Suppl 5): 2, 2002.
39. Johnson DH, Herbst R, Giaccone G et al: ZD1839 (Iressa) in combination with paclitaxel and carboplatin in chemotherapy-naïve patients with advanced non-small cell lung cancer (NSCLC): results from a phase III clinical trial (INTACT 2). Ann Oncol 13(Suppl 5): 127, 2002.
40. Herbst RS, Prager D, Hermann R et al: TRIBUTE - A phase III trial of Erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced NSCLC. J Clin Oncol 22 (No 14S) Abstr. 7011, 2004.
41. Gatzemeier U, Pluzanska A, Sczesma A et al: Results of a phase III trial of Erlotinib HCl (OSI-774) combined with cisplatin and gemcitabine chemotherapy in advanced NSCLC. J Clin Oncol 22 (No 14S) Abstr. 7010, 2004.
42. Schiller J, Langer J, Thor A et al: Trastuzumab in combination with paclitaxel/carboplatin in advanced non-small cell lung cancer: Final report of ECOG 2598. Proc Am Soc Clin Oncol #2606, 2003.
43. Gatzemeier U, Groth G, Van Zandwijk N et al: Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small cell lung cancer. Ann Oncol 15: 19-27, 2004.
44. Rosell R, Daniel C, Rumlau R et al: Randomized phase II study of Cetuximab in combination with Cisplatin and Vinorelbine vs. Cisplatin, Vinorelbine alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small cell lung cancer. J Clin Oncol 22 (No 145) Abstr. 7012, 2004.
45. Lynch TJ, Raju R, Lind M et al: Randomized phase II trial of chemotherapy and antisense oligonucleotide LY9000003 (ISIS 3521) in patients with advanced NSCLC. Lung Cancer 41(suppl 2): 35, 2003.
46. Shepherd F, Pereira J, Ciuleanu TE et al: A randomized placebo-controlled trial of Erlotinib in patients with advanced non-small cell lung cancer following failure of first-/second-line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 22 (No 14S) Abstr. 7022, 2004.